At Cleveland Clinic Health System, we believe in a better future for healthcare. And each of us is responsible for honoring our commitment to excellence, pushing the boundaries and transforming the patient experience, every day. We all have the power to help, heal and change lives — beginning with our own. That’s the power of the Cleveland Clinic Health System team, and The Power of Every One. Highly motivated individuals with a PhD or MD/PhD in relevant area are encouraged to apply. This training position, under the direct supervision of a Cleveland Clinic Principal Investigator will provide practical training and experience in a research setting. This position is appointed through Cleveland Clinic Research. The successful applicant will be able to demonstrate a commitment to research, a collaborative work ethic and strong communication skills, both written and verbal. This program is expected to be completed within 5 years. Compensation follows the NIH NRSA Postdoctoral Salary Scale based on total years of postdoctoral experience. Immune checkpoint blockade has transformed cancer immunotherapy. The Wang laboratory was among the first to identify VISTA (V-domain Immunoglobulin Suppressor of T Cell Activation) as a promising immune checkpoint target for cancer therapy (1-4). Current multidisciplinary projects focus on the epigenetic and metabolic regulation of tumor-reactive T cells, CAR T cells, tumor-associated macrophages, and myeloid-derived suppressor cells (MDSCs). These studies integrate basic and clinical research, providing a strong training environment in translational cancer immunology. We seek candidates with a recent PhD and with research experience in Biochemistry, Cell Biology, and Immunology to join our team. Interested applicants should submit a CV, a cover letter describing research interests, and contact information for three references to Dr. Li Lily Wang, [email protected]. References: 1. Le Mercier I, Chen W, Lines JL, Day M, Li J, Sergent P, Noelle RJ, Wang L (2014) VISTA regulates the development of protective anti-tumor immunity. Cancer Research, 74:1933-1944. PMC4116689 2. Xu W, Tạ MH, Malarkannan S, Wang L (2018) Review: The structure, expression, and function of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation. Cellular & Molecular Immunology. 2018 May 15(5):438-446 PMC6068175 3. Zhang K, Zakeri A, Alban T, Dong J, Ta HM, Zalavadia AH, Branicky A, Zhao H, Juric I, Husich H, Parthasarathy PB, Rupani A, Drazba JA, Chakraborty AA, Ching-Cheng Huang S, Chan T, Avril S, Wang LL. VISTA promotes the metabolism and differentiation of myeloid-derived suppressor cells by STAT3 and polyamine-dependent mechanisms. Cell Reports 2024 Jan 3;43(1):113661. doi: 10.1016/j.celrep.2023.113661. PMID: 38175754. 4. Hieu Minh Ta, Dia Roy, Keman Zhang, Tyler Alban, Ivan Juric, Juan Dong, Sachin Patnaik, Cassandra Gilmour, Amin Zakeri, Prerana B Parthasarathy, Amit Rupani, Yee Peng Phoon, Brian Gastman, Timothy Chan, Li Lily Wang. LRIG1 engages ligand VISTA and impairs tumor-specific CD8+ T cell responses. Science Immunology, 2024 May 17;9(95) PMID: 38758807 DOI: 10.1126/sciimmunol.adi7418 Principal Investigator: Lily Wang, PhD Cleveland Clinic Research Department: Cancer Sciences (THOR) Lab Research Topics: Next-generation Immune checkpoint protein tumor immunology Tumor-associated macrophages T cell biology For more information about the lab’s research, please visit: https://www.lerner.ccf.org/translational-hematology-oncology/wang/or contact Dr. Wang at [email protected]
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Entry Level
Education Level
Ph.D. or professional degree
Number of Employees
5,001-10,000 employees